PPD Testing Clause Samples
The PPD Testing clause establishes requirements for tuberculosis screening using the Purified Protein Derivative (PPD) test. It typically mandates that individuals, such as employees or students in certain settings, undergo PPD testing to confirm they are not carriers of active tuberculosis. This clause often outlines the frequency of testing, documentation procedures, and steps to take if a test result is positive. Its core practical function is to ensure public health and safety by preventing the spread of tuberculosis within organizations or institutions.
PPD Testing. Resident agrees to undergo annual PPD testing by the Employee Health Office of NCH, at NCH’s expense.
PPD Testing. The Employer shall also provide an annual Tuberculosis Screening and/or Purified Protein (PPD) or other test deemed appropriate by the Employer to all nurses covered by this Agreement.
PPD Testing. 93 26.10 APPENDIX X: INDUCTION THERAPY FLOW CHART ......................... 97 26.11 APPENDIX XI: OVERALL STUDY FLOW CHART ............................ 98 26.12 APPENDIX XII: VACCINATION INSTRUCTIONS ........................... 99 26.13 APPENDIX XIII: LIST OF ABBREVIATIONS ............................. 100 26.14 APPENDIX XIV: STUDY ACKNOWLEDGMENT ............................... 102 [LOGO] The SILV▇ ▇▇▇dy --------------------------------------------------------------------------------
PPD Testing. The reaction to intracutaneously injected tuberculin is a delayed (cellular) hypersensitivity reaction. The reaction which characteristically shows a delayed course, reaching its peak more than 24 hours after administration, consists of induration due to cell infiltration and occasionally vesiculation and necrosis. Clinically, a delayed hypersensitivity reaction to tuberculin is a manifestation of previous infection with M. Tuberculosis or a variety of non-tuberculosis bacteria. In most cases sensitization is induced by natural mycobacterial infection or by vaccination with BCG Vaccine. The sensitization following infection with mycobacteria occurs primarily in the regional lymph nodes. Small lymphocytes (T lymphocytes) proliferate in response to the antigenic stimulus to give rise to specifically sensitized lymphocytes. After several weeks, these lymphocytes enter the blood stream and circulate for long periods of time. Subsequent re-stimulation of these sensitized lymphocytes with the same or a similar antigen, such as the intradermal injection of tuberculin, evokes a local reaction mediated by these cells. The tuberculin reaction is characterized by the early predominance of mononuclear cells (small and medium sized lymphocytes and monocytes). Only a small proportion of these cells appear to be lymphocytes sensitized to tuberculin. Most cells are brought into the reaction through the release of biologically active substances by sensitized lymphocytes. An increase in vascular permeability leading to erythema and edema also occurs in tuberculin reactions. Characteristically, delayed hypersensitivity reactions to tuberculin begin at 5 to 6 hours, are maximal at 48 to 72 hours and subside over a period of days. In those who are elderly or those who 93/102 111 [LOGO] The SILV▇ ▇▇▇dy -------------------------------------------------------------------------------- are being tested for the first time reactions may develop slowly and may not peak until after 72 hours. Immediate hypersensitivity reactions to tuberculin or to constituents of the diluent can also occur. Not all infected persons will have a delayed hypersensitivity reaction to a tuberculin test. A large number of factors has been reported to cause a decreased ability to respond to the tuberculin test in the presence of tuberculous infection including viral infections (measles, mumps, chickenpox), live virus vaccinations (measles, mumps, polio), overwhelming tuberculosis, other bacterial infections, ...